Merck to sell global consumer health business to P&G for $4.2bn
Merck has agreed to sell its global consumer health business to Procter & Gamble (P&G) for about €3.4bn ($4.2bn).
Merck has agreed to sell its global consumer health business to Procter & Gamble (P&G) for about €3.4bn ($4.2bn).
US-based global private equity firm Advent International has entered into exclusive talks to acquire Sanofi’s European generics business, Zentiva, for €1.9bn.
French pharmaceutical firm Servier has signed an agreement to acquire the oncology business of Shire for $2.4bn.
Helsinn has agreed to acquire worldwide rights to Valchlor/Ledaga (mechlorethamine/chlormethine), an alkylating agent for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), from Actelion Pharmaceuticals.
Cipher Pharmaceuticals has entered into a definitive arrangement agreement to acquire the Canadian business portfolio of Cardiome Pharma.
Researchers from European Molecular Biology Laboratory (EMBL) have revealed that one in four drugs with human targets could affect the growth of bacteria in the human gut.
Biogen and AbbVie are withdrawing their multiple sclerosis (MS) drug Zinbryta (daclizumab) from global market after reports of eight cases of serious brain inflammation.
French drugmaker Sanofi has agreed to acquire US-based biotechnology firm Bioverativ for about $11.6bn.
Cell and Gene Therapy (CGT) Catapult and Sweden-based CombiGene have signed an agreement to develop manufacturing process for novel gene therapy to treat epilepsy.
A new partnership between Regeneron Pharmaceuticals and five other drug manufacturers intends to accelerate the generation of genetic exome sequence data from the 500,000 participants of the UK Biobank.